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ABSTRACT Latent tuberculosis infection (LTBI) screening is an important intervention for tuberculosis
(TB) elimination in low-incidence countries and is, therefore, a key component of England’s TB control
strategy. This study describes outcomes from a LTBI screening programme in a high-incidence area to
inform national LTBI screening in England and other low-incidence countries.
We conducted a retrospective cohort study of LTBI screening among eligible migrants (from high-
incidence countries and entered the UK within the last 5 years), who were identified at primary-care
clinics in Newham, London between August 2014 and August 2015. Multivariable logistic regression was
used to identify factors associated with LTBI testing uptake, interferon-γ release assay (IGRA) positivity
and treatment uptake.
40% of individuals offered LTBI screening received an IGRA test. The majority of individuals tested
were 16–35 years old, male and born in India, Bangladesh or Pakistan. Country of birth, smoking status
and co-morbidities were associated with LTBI testing uptake. IGRA positivity was 32% among those tested
and was significantly associated with country of birth, age, sex and co-morbidities.
This study identifies factors associated with screening uptake, IGRA positivity and treatment uptake,
and improves understanding of groups that should be supported to increase acceptability of LTBI testing
and treatment in the community.
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Introduction
The World Health Organization’s “End TB Strategy” aims to significantly reduce global tuberculosis (TB)
incidence and mortality [1]. The strategy also aims for TB elimination (defined as incidence of <1 per
1000000 people) in low-incidence countries. One of the main interventions to achieve these goals is latent
TB infection (LTBI) screening of high-risk groups, including migrants, to prevent re-activation [2].
In 2014, there were 6520 cases of TB notified in England, a rate of 12.0 cases per 100000 [3]. Nearly
three-quarters (72.2%) of all TB cases were notified among the foreign-born population and the vast
majority (86.0%) of foreign-born cases were notified among settled migrants who had been in the UK for
more than 2 years [3]. It is likely that the overwhelming majority of TB cases in the foreign-born
population are due to reactivation of LTBI acquired before arrival in the UK, a pattern which has been
observed in other countries [3–5].
It is well known that treatment for LTBI is efficacious in preventing active TB [6, 7]. Studies in the UK
have also shown that targeted programmes using primary-care registers [8] and interferon-γ release assays
(IGRA) to screen those most at risk of developing active TB are more effective in identifying LTBI cases,
preventing active TB and are cost effective [9, 10]. Based on this evidence, new entrant LTBI testing and
treatment became a key intervention of the Collaborative TB Strategy for England 2015–2020, which aims
to reduce TB incidence in England and reduce health inequalities from TB over the next 5 years [11].
Systematic national implementation of the LTBI programme is essential to achieving the aims of the
collaborative strategy and supports the WHO goal of TB elimination.
In 2014, the London borough of Newham established a primary-care based LTBI screening and treatment
service in response to its high TB incidence: the 3-year average TB incidence was 100 per 100000 (2012–
2014), higher than the average incidence in London (35.4 per 100000) [3]. More than half of the
population in Newham (54%) were born outside the UK and 86% of active TB cases in 2014 were notified
among the foreign-born population [12, 13]. The high TB rates in Newham and novel approach to TB
control led to the programme being selected as a pilot for the national LTBI programme.
This study describes the screening outcomes of the LTBI testing and treatment pilot in Newham and
determines factors contributing to LTBI screening uptake, IGRA test positivity and treatment uptake in
order to inform LTBI screening programmes in England and other low-incidence countries.
Methods
Study design and cohort
We conducted a retrospective cohort study. We included all individuals identified as eligible for LTBI
testing and treatment from 59 general practices (GPs) in the London borough of Newham between August
2014 and August 2015. Eligibility criteria included documented migrants who were born or who had spent
⩾6 months in a high-incidence country (⩾150 per 100000 and sub-Saharan Africa) and had entered the
UK within the last 5 years. Based on criteria for programmatic screening in the UK, individuals with
pre-existing or previously treated LTBI or active TB were not eligible for testing and therefore not included
in this study.
Screening process
The screening algorithm is outlined in figure 1. Eligible individuals were identified upon registering with a
GP and offered LTBI testing. A single IGRA test was used to screen individuals. Individuals found to be
IGRA positive were tested for HIV, hepatitis B and hepatitis C, and then reviewed by a GP to exclude
active TB based on a history, physical examination and chest radiography. Individuals with signs or
symptoms of suspected active TB (table 1), underlying liver disease or positive viral serology were referred
to the local TB clinic in secondary care.
All other individuals diagnosed with LTBI (table 1) were prescribed 3 months of rifampicin and isoniazid
combination therapy by the GP as recommended by national and international guidelines [14, 15].
Electronic prescriptions were sent to accredited community pharmacists who had been trained in
providing LTBI treatment.
Support statement: M. Burman was funded by Bart's Charity and D. Zenner is affiliated with the National Institute for
Health Research Health Protection Research Unit (NIHRHPRU) in Respiratory Infections at Imperial College London
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Data collection and cleaning
Data was collected using a bespoke template within the GP’s electronic patient record system (EMISWeb;
EMIS Health, Leeds, UK). Demographic information (age, sex, country of birth), co-morbidities
(immunosuppression, diabetes mellitus, pre-existing lung, chronic liver disease and chronic kidney disease)
and LTBI screening data (IGRA test result, HIV test result, hepatitis B and C serology results, electronic
prescription for treatment and reason for referral to secondary care) were extracted from EMISWeb. The
GP surgeries within Newham were categorised geographically into eight clusters responsible for the
provision of care in that area, labelled Cluster 1–8.
Dates when LTBI testing was offered, the IGRA result was logged in the GP data system and the electronic
prescription for treatment was issued were validated against each other and errors were excluded.
Statistical analysis
Logistic regression was performed for three steps along the patient pathway: LTBI testing uptake, IGRA
positivity and LTBI treatment uptake (table 2). We report on LTBI testing uptake, not coverage (defined as
those who accepted test among those who were eligible for screening). Although coverage is important
from a population perspective, we estimate these figures from cumulative area returns, as we do not hold
individual level data and do not present these here as not deemed robust enough. Analysis on treatment
completion was beyond the scope of this paper, due to LTBI treatment being dispensed through
pharmacists and therefore the data on treatment outcome was held in another database that is not












IGRA test not done:
  Declined (n=1254)
  No IGRA test results (n=2068)
IGRA test done
(n=2269)
LTBI treatment started by GP
(n=449)




Referred to secondary care TB 
clinic for treatment
(n=83)
FIGURE 1 Latent tuberculosis infection (LTBI) testing and treatment programme flow chart. IGRA: interferon-γ
release assay; GP: general practitioner; TB: tuberculosis.
TABLE 1 Definitions for LTBI and active TB cases
Case term Definition
LTBI IGRA test positivity and no clinical signs or symptoms suggestive of active TB.
Active TB Culture confirmed disease due to Mycobacterium tuberculosis complex or in the absence of
culture confirmation, a case with clinical signs and/or radiological signs and/or
symptoms compatible with active TB and the TB clinician decided to treat the individual
with a full course of anti-TB treatment.
LTBI: latent tuberculosis infection; TB: tuberculosis; IGRA: interferon-γ release assay.
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currently linked to the primary care GP data. Demographic characteristics, co-morbidities and GP
categories were used to compare eligible individuals at each step and odds ratios were calculated. Three
forward stepwise multivariable logistic regression models were created, and a p-value of <0.05 was used to
retain the variable in the model.
The time to take up LTBI testing was calculated as the time between the date that LTBI screening was
offered and the date that the IGRA result was logged in the GP data system. Only individuals with an
IGRA result were included in the LTBI testing delay analysis. LTBI testing delay was defined as more than
3 months between being offered LTBI testing and having the IGRA test done. The time to take up LTBI
treatment was calculated using the time between the date that the IGRA result was logged and the date the
electronic prescription for LTBI treatment was issued. Only those with an electronic prescription were
included in the LTBI treatment delay analysis. LTBI treatment delay was defined as more than 1 month
between having an IGRA test done and being prescribed LTBI treatment. Both LTBI testing and treatment
delays were defined based on the distribution of the data and descriptively compared against demographic
characteristics. Individuals missing required data to calculate delays were excluded from the analysis. There
were no demographic differences between those with dates and those without. Demographic and GP
factors were tested using univariable logistic regression to find associations with either LTBI testing delay
or treatment delay.
Data were managed and analysed using Excel (Microsoft; Redmond, WA, USA) and STATA 13 (Statacorp;
College Station, TX, USA).
Results
In total, 5591 individuals were offered LTBI testing between August 2014 and August 2015 in the London
Borough of Newham. Most individuals were aged 16–35 years (3968; 71.0%), were male (3028; 54.2%) and
born in the Indian sub-continent (4387; 78.5%) (table 3). The five most common countries of birth of
individuals offered LTBI testing were Bangladesh (1697; 30.3%), India (1684; 30.1%), Pakistan (851;
15.2%), Nigeria (351; 6.3%) and Somalia (189; 3.4%) (Appendix 1 in the supplementary file). 539 (9.6%)
individuals offered LTBI testing had at least one co-morbidity and 840 (15.0%) were current smokers
(table 3).
LTBI testing uptake
Of those individuals offered LTBI testing, 2269 (40.6%) had an IGRA test done, 1254 (22.4%) declined
LTBI testing and 2068 (37.0%) had no IGRA result recorded (figure 1). There were no demographic
differences between those who had declined LTBI testing and those who had been offered but had no
IGRA result; therefore, all were considered as not having an IGRA test for the purpose of the analysis.
Overall, LTBI testing uptake was highly variable month to month during the time period (between 38.1%
and 60.4%) and also varied by GP surgery with zero to 88.8% of individuals taking up LTBI testing.
The multivariable model for LTBI testing uptake, which adjusted for age, sex and all significant variables
from univariable analysis, showed that individuals from East and South-East Asia and from sub-Saharan
Africa were significantly less likely to take up LTBI testing compared with individuals from the Indian
sub-continent (aOR 0.6 (95% CI, 0.4–0.9) and aOR 0.7 (95% CI, 0.6–0.8) respectively) (table 4).
Individuals who currently smoked were less likely to take up LTBI testing (aOR 0.8 (95% CI, 0.7–0.9)) and
those with chronic liver disease were more likely to take up LTBI testing (aOR 1.6 (95% CI, 1.1–2.5)).
Diabetes mellitus was not significant in the multivariable model because age was a confounding factor, as
77.4% of diabetics were more than 36 years old. We compared the multivariable model with and without
age and could validate the odds ratio for LTBI testing uptake among diabetics and, although it is strongly




LTBI testing uptake The number of eligible individuals with an IGRA test result recorded among those
who had been offered LTBI testing.




The number of eligible individuals with a logged electronic prescription among of all
with a positive IGRA test result.
LTBI: latent tuberculosis infection; IGRA: interferon-γ release assay.
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influenced by age, diabetics are more likely to take up LTBI testing. The multivariable analysis was
repeated excluding all individuals who were offered testing but had no IGRA result and the results were
broadly similar.
The median (interquartile range) time to take up LTBI testing was 1.5 (0.4–3.4) months; almost half
(46.8%) of those who accepted LTBI testing had a delay of more than 1 month and 24.9% had a delay of
more than 3 months. There were no significant differences in demographic characteristics between those
that had a testing delay of less than 3 months and more than 3 months, and no difference in testing delay
by IGRA result. The proportion of cases that experienced a testing delay varied by GP surgery from 0 to
100% experiencing a delay of more than 3 months. Among the eight GP surgery clusters, Cluster 3 had a
significantly higher proportion of individuals who experienced a testing delay compared to Cluster 1,
which offered the highest number of IGRA tests (OR 1.8 (95% CI, 1.1–2.8)) (table 5).
IGRA test positivity
A total of 719 (31.7%) individuals tested positive by IGRA, 1545 (68.1%) had a negative result and five
(0.2%) had an indeterminate result (figure 1). IGRA positivity increased with age: 25.8% among 16–
35 year olds, 45.4% in 36–50 year olds and 51.2% in those over 50 years old. The multivariable model
showed that males, those aged over 36 years old, those born in sub-Saharan Africa and individuals with
diabetes mellitus were significantly more likely to test positive after adjusting for sex, age and significant
variables from the univariable analysis (aOR 1.4 (95% CI, 1.2–1.7), aOR 2.1 (95%CI, 1.7–2.6), aOR 2.5
(95% CI, 1.7–3.7), aOR 1.6 (95% CI, 1.3–2.1), aOR 1.6 (95% CI, 1.1–2.3)) (table 6). Positive
Bacillus Calmette–Guérin vaccination status was inversely correlated with IGRA positivity (OR 0.2 (95%
CI, 0.1–0.9)).
LTBI treatment uptake
Among individuals with a positive IGRA result, 616 (85.7%) had attended a GP consultation to rule-out
active TB (figure 1). Overall 83 individuals were referred to the TB clinic for specialist care because of HIV
TABLE 3 Baseline characteristics of all individuals offered latent tuberculosis infection testing
n (%)
Age group
<16 years 44 (0.8)
16–35 years 3968 (71.0)
36–50 years 1344 (26.9)





East and South-East Asia 137 (2.5)
Eastern Europe 8 (0.1)
Northern Africa 11 (0.2)
Southern Asia 4387 (78.5)
Sub-Saharan Africa 1048 (18.7)









Diabetes mellitus 287 (5.1)
Pre-existing lung disease 182 (3.3)
Chronic liver disease 89 (1.6)
Chronic kidney disease 25 (0.5)
Any comorbidity 539 (9.6)
Current smoker 840 (15.0)
#: See appendix 1 in the online supplementary material for all countries of birth listed.
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(two individuals), hepatitis C (three) or hepatitis B (six) co-infection, or due to suspected active TB in
individuals with at least one TB-related symptom (22) or an abnormal chest radiograph (five). The majority
(40) of referred cases did not have a reason for referral recorded. Among those referred, a total of 11 active
TB cases were notified, which accounts for a detection rate of 484.8 per 100000 individuals screened.
In total 449 (62.5%) of those with a positive IGRA test took up LTBI treatment. LTBI treatment uptake
varied between 37.5% in August 2014 and 58.5% in July 2015; however, the increase was not significant
TABLE 4 Logistic regression model for latent tuberculosis infection (LTBI) testing uptake, comparing individuals with an
interferon-γ release assay (IGRA) test result (IGRA done) to individuals who were offered LTBI testing but had no recorded
IGRA test result (IGRA not done)






Univariable analysis Multivariable analysis
OR 95% CI p-value aOR 95% CI p-value Likelihood
ratio
Age group 0.002
<16 years 26 (59.1) 18 (40.9) 1.1 0.6–1.9 0.9 1.1 0.6–2.0 0.7
16–35 years 2396 (60.4) 1572 (39.6) Comparison group Comparison group
36–50 years 788 (58.6) 556 (41.4) 1.1 0.9–1.2 0.2 1.1 1–1.3 0.03
>50 years 112 (47.7) 123 (52.3) 1.7 1.3–2.2 <0.001 1.8 1.4–2.4 <0.001
Sex 0.8
Female 1527 (59.6) 1036 (40.4) Comparison group Comparison group
Male 1795 (59.3) 1233 (40.7) 1.01 0.9–1.1 0.8 1 0.9–1.1 0.8 0.8523
Region of birth <0.001
East and South-East Asia 99 (72.3) 38 (27.7) 0.5 0.3–0.7 0.001 0.6 0.4–0.9 0.02
Eastern Europe 3 (37.5) 5 (62.5) 2.2 0.5–9.3 0.3 2.5 0.6–10.5 0.2
Northern Africa and Middle
East
7 (63.6) 4 (36.4) 0.8 0.2–2.6 0.7 0.7 0.2–2.5 0.6
Southern Asia 2512 (57.3) 1875 (42.7) Comparison group Comparison group
Sub-Saharan Africa 701 (66.9) 347 (33.1) 0.6 0.6–0.8 <0.001 0.7 0.6–0.8 <0.001 <0.001
BCG 0.2
No 3299 (59.5) 2246 (40.5) Comparison group
Yes 23 (50.0) 23 (50.0) 1.5 0.8–2.6 0.2
Immunosuppression 0.4
No 3321 (59.4) 2269 (40.6) Comparison group
Yes 1 (100.0) 0 (0.0) n/a n/a n/a
Diabetes mellitus 0.04
No 3168 (59.7) 2136 (40.3) Comparison group Comparison group
Yes 154 (53.7) 133 (46.3) 1.3 1–1.6 0.04 1.04 0.8–1.3 0.8 0.7134
Pre-existing lung disease 0.98
No 3214 (59.4) 2195 (40.6) Comparison group
Yes 108 (59.3) 74 (40.7) 1 0.7–1.3 0.98
Chronic liver disease 0.03
No 3279 (59.6) 2223 (40.4) Comparison group Comparison group
Yes 43 (48.3) 46 (51.7) 1.6 1.04–2.4 0.03 1.6 1.1–2.5 0.02 0.0341
Chronic kidney disease 0.6
No 3306 (59.4) 2260 (40.6) Comparison group
Yes 16 (64.0) 9 (36.0) 0.8 0.4–1.9 0.6
Current smoker 0.006
No 2787 (58.7) 1964 (41.3) Comparison group Comparison group
Yes 535 (63.7) 305 (36.3) 0.8 0.7–0.9 0.006 0.8 0.7–0.9 0.01 0.0031
General practice group <0.001
Cluster 1 930 (67.9) 440 (32.1) Comparison group Comparison group
Cluster2 258 (63.2) 150 (36.8) 1.2 1.0–1.5 0.08 1.2 1.0–1.5 0.09
Cluster 3 412 (50.7) 401 (49.3) 2.1 1.7–2.5 <0.001 2.0 1.7–2.4 <0.001
Cluster 4 463 (49.4) 475 (50.6) 2.2 1.8–2.6 <0.001 2.1 1.8–2.5 <0.001
Cluster 5 512 (62.6) 306 (37.4) 1.3 1.1–1.5 0.01 1.3 1.1–1.6 0.006
Cluster 6 285 (51.6) 267 (48.4) 2.0 1.6–2.4 <0.001 2.0 1.6–2.5 <0.001
Cluster 7 287 (70.7) 119 (29.3) 0.9 0.7–1.1 0.3 0.9 0.7–1.2 0.7
Cluster 8 131 (61.2) 83 (38.8) 1.3 1.0–1.8 0.05 1.5 1.1–2.0 0.01 <0.001
#: proportions calculated out of each characteristic as row proportions.
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(p=0.1). No demographic or clinical factors were significantly associated with individuals being prescribed
treatment over those that were not prescribed treatment (table 7). Although not significant, a higher
proportion of men with an IGRA positive result were prescribed treatment, which may in part be due to
pregnant women with a positive IGRA result not being prescribed treatment. Treatment uptake varied by
GP surgery from 0 to 100% of LTBI cases taking up treatment. Accounting for demographic and clinical
factors, GP surgery clusters 3 and 4 were significantly less likely to prescribe treatment compared with the
GP cluster 1 ((aOR 0.6 (95% CI, 0.3–0.9) and aOR 0.3 (95% CI, 0.2–0.5)).
The median (interquartile range) time to take up treatment for individuals with a positive IGRA result was
17 (0–40) days. 138 (32.9%) individuals had a LTBI treatment delay of more than 1 month. There were no
demographic or clinical factors associated with treatment delay. However, the proportion of cases that
experienced treatment delay varied by GP surgery from 0 to 100%. Among the eight clusters of GP
surgeries, four had a significantly higher proportion of LTBI cases who experienced a treatment delay of
more than 1 month when compared with GP cluster 1 (table 5).
Discussion
This paper reports on the first year of a large community-based LTBI testing and treatment programme in
the London borough of Newham. Overall screening uptake was low but we identified key demographic,
clinical and provider factors associated with low uptake and therefore, lessons learned from Newham
contain important policy implications for the implementation of LTBI testing and treatment in England
and other low TB incidence countries.
Overall, less than half of the eligible population were tested for LTBI during the first year of the
programme in Newham. A similarly large drop-off at this stage of the LTBI cascade of care was reported
in a recent systematic review [16]. IGRA positivity was 32% in our study partly due to the inclusion of an
older population in the first year of the pilot but also because the targeted population were screened based
on country of birth. In this respect, our study was similar to other studies among migrant populations,
where IGRA positivity varied between 25% and 30% and having LTBI was associated with increasing
in-country TB incidence and age [17–20]. Overall, LTBI screening uptake and IGRA positivity were
associated with demographic, clinical and provider related factors, whereas LTBI treatment uptake was
exclusively provider-dependent and varied greatly by GP surgery. Our study also identified 11 active TB
cases, which demonstrates the potential for LTBI screening programmes to have a larger impact on
reducing further transmission of TB, thus reducing significant morbidity and mortality.
We examined factors associated with LTBI testing uptake, which may allow for more targeted
interventions to increase acceptance of the programme. Country of birth was an important influencing
factor for both LTBI testing uptake and IGRA positivity because individuals from sub-Saharan Africa were
less likely to take up testing whilst having a higher IGRA test positivity. This demonstrates the need for
targeted interventions for the most at-risk patient populations. In the literature small-scale, setting-specific
studies on LTBI screening have been described and systematic reviews on LTBI treatment uptake and
completion have shown varied associations with migrant or refugee populations [21,22]. We are not aware













LTBI test offered and IGRA test done








<1 month >1 month Univariable
analysis
OR 95% CI p-value n (%#) n (%#) OR 95% CI p-value
Cluster 1 8 7620 164 (74.2) 57 (25.8) Comparison group 73 (82.9) 15 (17.1) Comparison group
Cluster 2 6 6422 52 (80.0) 13 (20.0) 0.7 0.4–1.4 0.3 22 (88.0) 3 (12.0) 0.7 0.2–2.5 0.5
Cluster 3 8 3618 167 (82.3) 36 (17.7) 0.6 0.4–1.0 0.05 40 (52.6) 36 (47.4) 4.4 2.1–9.0 <0.001
Cluster 4 7 7002 75 (62.0) 46 (38.0) 1.8 1.1–2.8 0.02 40 (64.5) 22 (35.5) 2.7 1.2–5.7 0.01
Cluster 5 11 6740 44 (67.7) 21 (32.3) 1.4 0.7–2.5 0.3 29 (46.8) 33 (53.2) 5.5 2.6–11.7 <0.001
Cluster 6 6 7034 61 (69.3) 27 (30.7) 1.3 0.7–2.2 0.4 36 (66.7) 18 (33.3) 2.4 1.1–5.4 0.03
Cluster 7 6 6870 38 (82.6) 8 (17.4) 0.6 0.3–1.4 0.2 28 (82.3) 6 (17.7) 1 0.4–3.0 0.9
Cluster 8 4 9858 45 (90.0) 5 (10.0) 0.3 0.1–0.8 0.02 7 (87.5) 1 (12.5) 0.7 0.1–6.1 0.7
#: Proportions calculated out of each general practice cluster as row proportions. IGRA: interferon-γ release assay.
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of any other study which has examined additional demographics such as country of birth in detail,
however other disease screening initiatives such as HPV vaccination [23] and HIV testing [24] have
demonstrated similar differences among ethnic minorities.
Pre-existing health conditions may influence LTBI testing uptake. Individuals with diabetes mellitus or
chronic liver disease were more likely to take up LTBI testing when offered. This may be because these
individuals know they are at higher risk of progression from LTBI to active TB, and increased access to
care through monitoring of their diabetes, which in turn influence health-seeking behaviour [25–27].
Populations with co-morbidities have been found in other studies to have higher LTBI treatment
completion rates when compared with other populations, which could indicate greater concern about their
own health or better access to care for persons with chronic conditions [16,22]. Older individuals were
also more likely to take up LTBI testing and had higher IGRA positivity which may be confounded by
older individuals having more co-morbidities, but may also be influenced by similar health-seeking
behaviour. Conversely, other studies have shown that current smokers or individuals with social risk
factors, such as homelessness, injecting drug use and/or alcohol use are less likely to adhere to LTBI
treatment, which supports our finding that current smokers were less likely to take up LTBI testing and
suggests that health-seeking behaviours and access to care play an important role in LTBI testing and
treatment programmes [21,22,28].
We tested all demographic and clinical factors and found no correlation with treatment uptake; however,
the same model showed that treatment uptake varied widely by GP surgery and several geographic GP
clusters were more likely to prescribe LTBI treatment than others. This association with providers can be
TABLE 6 Logistic regression model for interferon-γ release assay (IGRA) test positivity, comparing individuals with a positive
IGRA test result to individuals with a negative IGRA test result
Characteristic IGRA negative IGRA positive Chi-squared Univariable analysis Multivariable analysis
n (%#) n (%#) p value OR 95% CI p value aOR 95% CI p value Likelihood ratio
Age group <0.001
<16 18 (100.0) 0 (0.0)
16–35 1166 (74.2) 406 (25.8) Comparison group Comparison group
36–50 301 (54.6) 250 (45.4) 2.4 1.9–2.9 <0.001 2.1 1.7–2.6 <0.001
>50 60 (48.8) 63 (51.2) 3.0 2.1–4.4 <0.001 2.5 1.7–3.7 <0.001
Sex <0.001
Female 748 (72.3) 286 (27.7) Comparison group Comparison group
Male 797 (64.8) 433 (35.2) 1.4 1.2–1.7 <0.001 1.4 1.2–1.7 <0.001 0.0010
Region of birth
East and South East Asia 27 (71.1) 11 (28.9) 0.96 0.5–2.0 0.9 0.8 0.4–1.7 0.6
Eastern Europe 2 (40.0) 3 (60.0) 3.5 0.6–21.2 0.2 4.4 0.7–27.4 0.1
Northern Africa and Middle East 3 (75.0) 1 (25.0) 0.8 0.1–7.6 0.8 0.6 0.06–6.4 0.7
Southern Asia 1314 (70.2) 557 (29.8) Comparison group Comparison group
Sub-Saharan Africa 199 (57.5) 147 (42.5) 1.7 1.4–2.2 <0.001 1.6 1.3–2.1 <0.001 0.0010
BCG 0.02
No 1525 (68.0) 717 (32.0) Comparison group Comparison group
Yes 20 (90.9) 2 (9.1) 0.2 0.1–0.9 0.04 0.4 0.1–1.7 0.2 0.0946
Diabetes mellitus <0.001
No 1479 (69.4) 653 (30.6) Comparison group Comparison group
Yes 66 (50.0) 66 (50.0) 2.3 1.6–3.2 <0.001 1.6 1.1–2.3 0.02 0.0240
Pre-existing lung disease 0.4
No 1498 (68.4) 692 (31.6) Comparison group Comparison group
Yes 47 (63.5) 27 (36.5) 1.2 0.8–2.0 0.4 1.04 0.6–1.7 0.9 0.8406
Chronic liver disease 0.003
No 1524 (68.7) 695 (31.3) Comparison group Comparison group
Yes 21 (46.7) 24 (53.3) 2.5 1.4–4.5 0.002 1.8 1.0–3.4 0.06 0.0728
Chronic kidney disease 0.1
No 1541 (68.3) 714 (31.7) Comparison group Comparison group
Yes 4 (44.4) 5 (55.6) 2.7 0.7–10.1 0.1 1.5 0.4–5.7 0.6 0.5764
Current smoker 0.8
No 1336 (68.2) 624 (31.8) Comparison group
Yes 209 (68.8) 95 (31.2) 0.97 0.8–1.3 0.8
#: Proportions calculated out of each characteristic as row proportions.
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explained by the differences in treatment delay, as GP surgeries that had longer treatment delays also had
patients who were less likely to take up treatment. LTBI testing and treatment programmes in primary care
can be complex and require training and incentives for GPs. A recent survey of GPs in England to find the
enablers and barriers to testing and treating LTBI in primary care also confirmed the importance of
training health care staff to feel confident in their work [29]. Training is provided to all GPs involved in
the Newham LTBI screening programme and is mandatory for them to attend in order to stay in the
programme; however, it is possible that implementation of the programme may differ based on available
resources to offer screening, availability of appointments to offer treatment, knowledge, skills and beliefs.
This study demonstrates the importance of identifying practices and clusters of practices with poorer
treatment uptake in order to more closely engage them in training and support activities.
TABLE 7 Logistic regression model for latent tuberculosis infection (LTBI) treatment prescription uptake, comparing
individuals with a positive interferon-γ release assay (IGRA) test result who had an electronic prescription for LTBI treatment













OR 95% CI p value OR 95% CI p value
Age group 0.6
<16 0 (0) 0 (0)
16–35 115 (38.2) 251 (61.8) Comparison group Comparison group
36–50 89 (35.6) 161 (64.4) 1.1 0.8–1.5 0.5 1.0 0.7–1.5 0.8
>50 26 (41.3) 37 (58.7) 0.9 0.5–1.5 0.6 0.9 0.5–1.6 0.6
Sex 0.07
female 119 (41.6) 167 (58.4) Comparison group Comparison group
male 151 (34.9) 282 (65.1) 1.3 0.9–1.8 0.07 1.4 1.0–2.0 0.06
Region of birth 0.7
East and South East Asia 5 (45.5) 6 (54.5) 0.7 0.2–2.3 0.6 0.5 0.1–1.7 0.3
Eastern Europe 2 (66.7) 1 (33.3) 0.3 0.03–3.3 0.3 0.3 0.02–3.2 0.3
Northern Africa and Middle
East
0 (0.0) 1 (100.0) - - - - - -
Southern Asia 207 (37.2) 350 (62.8) Comparison group Comparison group
Sub-saharan Africa 56 (38.1) 91 (61.9) 0.9 0.7–1.4 0.8 0.9 0.6–1.4 0.5
BCG 0.7
no 269 (37.5) 448 (62.5) Comparison group Comparison group
yes 1 (50.0) 1 (50.0) 0.6 0.04–9.6 0.70 0.3 0.02–5.7 0.4
Diabetes mellitus 0.4
no 242 (37.1) 411 (62.9) Comparison group Comparison group
yes 28 (42.4) 38 (57.6) 0.8 0.5–1.3 0.4 0.8 0.4–1.3 0.4
Pre-existing lung disease 0.9
no 260 (37.6) 432 (62.4) Comparison group Comparison group
yes 10 (37.0) 17 (63.0) 1.0 0.5–2.3 0.9 1.0 0.4–2.2 0.9
Chronic liver disease 0.2
no 258 (37.1) 437 (62.9) Comparison group Comparison group
yes 12 (50.0) 12 (50.0) 0.6 0.3–1.3 0.2 0.5 0.2–1.3 0.2
Chronic kidney disease 0.9
no 268 (37.5) 446 (62.5) Comparison group Comparison group
yes 2 (40.0) 3 (60.0) 0.9 0.1–5.4 0.9 0.9 0.1–5.9 0.9
Current smoker 0.3
no 239 (38.3) 385 (61.7) Comparison group Comparison group
yes 31 (32.6) 64 (67.4) 1.3 0.8–2.0 0.300 1.1 0.7–1.8 0.7
GP Practice group <0.001
Cluster 1 37 (28.0) 95 (72.0) Comparison group Comparison group
Cluster 2 11 (29.0) 27 (71.0) 0.9 0.4–2.1 0.9 0.9 0.4–2.0 0.8
Cluster 3 53 (38.7) 84 (61.3) 0.6 0.4–1.0 0.06 0.6 0.3–0.9 0.03
Cluster 4 82 (55.0) 67 (45.0) 0.3 0.2–0.5 <0.001 0.3 0.2–0.5 <0.001
Cluster 5 32 (34.0) 62 (66.0) 0.8 0.4–1.3 0.3 0.7 0.4–1.2 0.2
Cluster 6 25 (31.7) 54 (68.3) 0.8 0.4–1.5 0.6 0.8 0.4–1.4 0.4
Cluster 7 18 (31.6) 39 (68.4) 0.8 0.4–1.6 0.6 0.9 0.4–1.8 0.8
Cluster 8 5 (33.3) 10 (66.7) 0.8 0.2–2.4 0.7 0.8 0.2–2.6 0.7
#: Proportions calculated out of each characteristic as row proportions.
https://doi.org/10.1183/13993003.01226-2017 9
TUBERCULOSIS | M.G. LOUTET ET AL.
A higher proportion of men were prescribed LTBI treatment compared with women, which is most likely
due to the fact that pregnant women were not offered treatment until post-partum, as specified by the
early screening rules of the pilot site. Early results from this study demonstrating the risk of lower uptake
of women in childbearing age informed a revision of the pathway to allow for screening of pregnant
women and a call–recall system for treatment after pregnancy.
This study has several limitations. We present observational data, where data collection was not
mandatory. This could have led to missing data and potential loss of statistical power for some analysis.
We analysed and compared the baseline characteristics of those with complete records and with missing
data and found these were broadly comparable; we think it likely that data were missing at random, not
introducing bias. There may have also been coding errors used for categorising the co-morbidities;
however, we do not think this has an effect in the analysis because there were no systematic errors found
in the data. As this was an observational study, it is possible, that not all IGRA test results were recorded,
which could have decreased the LTBI testing uptake rate and could have resulted in an overestimation of
IGRA positivity if negative results were not recorded. However, we have no evidence for systematic
under-recording by demographic or provider characteristics. Another limitation was that we were not able
to report on LTBI screening coverage or on treatment outcomes, which were out of scope for this paper;
however, the absence of these indicators does not affect the validity of our findings from the screening
pathway.
In conclusion, our evaluation of the LTBI testing and treatment project in Newham illustrates the
feasibility and acceptability of primary-care based LTBI screening and treatment programmes. Our study
shows that particular migrant population groups require more patient engagement to ensure high testing
and treatment uptake particularly if uptake is low and/or LTBI positivity is high. This study also showed
the immediate impact that LTBI screening programmes have on TB control by identifying active TB cases
earlier, reducing further transmission. The testing and treatment delays found in this pilot were high and
possibly adversely impacted on uptake. The innovative approach to LTBI screening through primary-care
registrations has many positive implications on increasing accessibility within most migrant communities,
however, special programmes are needed to meet the needs of undocumented migrants, asylum seekers,
refugees and other underserved populations who may not engage with health services and therefore are
missed by this programme. Whilst this paper identifies important factors related to LTBI testing and
treatment uptake, larger studies are urgently needed to better understand the barriers and enablers to this
intervention in order for it to effectively contribute to TB elimination worldwide.
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